Renovaro (NASDAQ:RENB) Stock Price Up 2.3% – Here’s What Happened

Renovaro Inc. (NASDAQ:RENB)’s stock price shot up 2.3% on Friday . The company traded as high as $1.95 and last traded at $1.76. 801,579 shares traded hands during mid-day trading, an increase of 40% from the average session volume of 572,997 shares. The stock had previously closed at $1.72.

Renovaro Trading Up 2.3 %

The company’s 50 day simple moving average is $0.76 and its 200-day simple moving average is $0.93. The firm has a market cap of $279.35 million, a P/E ratio of -1.83 and a beta of 0.65.

Renovaro (NASDAQ:RENB) last issued its quarterly earnings data on Thursday, October 10th. The company reported ($0.45) earnings per share for the quarter.

Institutional Trading of Renovaro

Several large investors have recently modified their holdings of RENB. Barclays PLC increased its position in Renovaro by 315.7% during the third quarter. Barclays PLC now owns 69,531 shares of the company’s stock valued at $34,000 after acquiring an additional 52,804 shares during the last quarter. State Street Corp lifted its stake in shares of Renovaro by 3.8% in the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company’s stock worth $640,000 after purchasing an additional 48,114 shares during the period. Rhumbline Advisers bought a new position in shares of Renovaro in the 2nd quarter worth approximately $79,000. Finally, Bank of New York Mellon Corp bought a new stake in Renovaro during the second quarter valued at approximately $220,000. Institutional investors own 71.41% of the company’s stock.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.